We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a small, placebo-controlled study, vandetanib (Caprelsa), a kinase inhibitor, delayed progression of the most common type of thyroid cancer, French researchers reported. MedPage Today
